Dexmedetomidine + Midazolam
Phase 3Recruiting 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Delirium
Conditions
Delirium, Critical Illness, Sedation Complication, Executive Dysfunction, Post Traumatic Stress Disorder
Trial Timeline
May 10, 2021 → Sep 16, 2026
NCT ID
NCT04801589About Dexmedetomidine + Midazolam
Dexmedetomidine + Midazolam is a phase 3 stage product being developed by Pfizer for Delirium. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04801589. Target conditions include Delirium, Critical Illness, Sedation Complication.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04801589 | Phase 3 | Recruiting |
Competing Products
17 competing products in Delirium
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lemborexant 5 mg + Control (placebo) group | Eisai | Phase 2 | 52 |
| Suvorexant + Placebo | Merck | Phase 3 | 77 |
| Suvorexant 20 mg + Placebo | Merck | Phase 2 | 52 |
| Rivastigmine + Placebo | Novartis | Approved | 85 |
| Rivastigmine prevention of delirium | Novartis | Phase 3 | 77 |
| Rivastigmine transdermal patch + placebo patch | Novartis | Phase 3 | 77 |
| Rivastigmine Patch | Novartis | Approved | 85 |
| Dexmedetomidine + Placebo | Pfizer | Phase 3 | 76 |
| Parecoxib | Pfizer | Approved | 84 |
| Dexmedetomidine + Placebo | Pfizer | Phase 3 | 76 |
| Pregabalin | Pfizer | Phase 3 | 76 |
| Propofol + Dexmedetomidine | Pfizer | Pre-clinical | 22 |
| Dexmedetomidine + Saline placebo | Pfizer | Phase 2/3 | 64 |
| Cyclopofol + Propofol | Haisco Pharmaceutical Group | Approved | 82 |
| Dexmedetomidine + Sodium chloride 0.9% | Baxter | Phase 3 | 74 |
| Dexmedetomidine Hydrochloride Group | Brain Biotech | Approved | 77 |
| Dexmedetomidine sublingual film | BioXcel Therapeutics | Phase 2 | 44 |